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A B S T R A C T   
Drug delivery to the posterior segment of the eye is challenging due to several anatomical and physiological 
barriers. Thus, there is a need for prolonged action and targeted drug delivery to treat retinal diseases. Intra-
vitreal injections avoid anterior eye barriers, but the vitreoretinal interface and inner limiting membrane (ILM) 
may prevent access of drug delivery systems to the retina. Existing data on retinal permeation of intravitreal 
nanoparticles are sparse and probably misleading due to the inter-species differences of retinal structures in 
rodents and humans. To bridge this gap, retinal permeation of light-activated liposomes was studied in an ex vivo 
bovine explant system that simulates the structure of vitreoretinal interface and intact ILM. Our findings indicate 
that the particle size plays a significant role in determining the retinal penetration as the liposomes of >100 nm 
sized failed to overcome the ILM and could not permeate into the retina. In addition, our results demonstrate the 
impact of surface charge and PEG-coating on retinal penetration. Small (≈ 50 nm) anionic liposomes with PEG 
coating showed the most extensive distribution and cellular localization in the retina. In summary, this study 
extends understanding of ocular barriers, and provides valuable information to augment design of retinal drug 
delivery systems.   
1. Introduction 
Disease-related retinal damage is the leading cause of visual 
impairment and blindness in industrialized countries, imposing a huge 
burden on the economy and quality of patients’ lives [1,2]. The most 
prevalent posterior segment eye diseases are age-related and the number 
of patients suffering from such disorders increases with the aging of the 
global population [3,4]. Treatment of retinal diseases, such as age- 
related macular degeneration (AMD), diabetic retinopathy (DR) and 
glaucomatous retinal degeneration, is still challenging and new treat-
ments are needed. Retinal drug delivery is hampered by several ocular 
barriers (e.g. blood retinal barrier). Thus, retinal diseases cannot be 
treated by topical, systemic or periocular (e.g. sub-conjunctival and 
peribulbar) routes of administration, since adequate drug 
concentrations are not achieved in the retina. 
Intraocular modes of drug administration, such as intravitreal, sub-
retinal and suprachoroidal injections, are used in retinal drug delivery, 
but only intravitreal (IVT) injections are in worldwide clinical use [5]. 
IVT injections are used routinely in the anti-vascular endothelial growth 
factor (anti-VEGF) treatment of exudative age-related macular degen-
eration, representing 80.6% of the retinal therapeutics market (Market 
Scope Estimate, http://market-scope.com/). Clinically accepted IVT 
injections offer several advantages: 1) the drug is injected directly into 
the vitreous humour, resulting in retinal delivery, 2) the injections 
bypass several ocular barriers (e.g. blood-retinal barrier, blood-aqueous 
barriers, cornea, sclera), and 3) reduced systemic side effects. However, 
the injectable solutions require frequent IVT dosing that is problematic 
for the patients and healthcare system. The acceptable injection interval 
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depends on the disease state: in serious disease states (e.g. wet AMD) 
more frequent drug administrations can be accepted than in slowly 
progressing early stage disease (e.g. dry AMD). The injection intervals of 
anti-VEGF antibodies (e.g. bevacizumab) are 1–2 months which leads to 
reduced patient compliance and sub-optimal treatment outcomes. In the 
case of small molecule drugs, the dosing intervals would be too short (a 
few days) for clinical purposes as the intravitreal half-lives of small 
molecules are usually less than 10 h [6]. There is an unmet need to 
develop retinal drug delivery systems with prolonged injection intervals 
and effective retinal permeation. 
Over the last decades, numerous viral and non-viral nanoparticles 
have been investigated for retinal delivery of drugs and genes [7–10]. 
Currently, sub-retinal injections are considered to be the most effective 
mode of retinal nanoparticle delivery, but these injections are much 
more demanding in clinical practice than IVT delivery. The sub-retinal 
injections are not widely accepted in the clinical practice and may 
never become widely used in the clinics. Effective IVT delivery of 
nanoparticles to the retina may enable wide clinical use of viral and non- 
viral therapeutics in the retinal diseases. 
Currently, retinal delivery of IVT nanocarriers is hindered by two 
barriers: vitreous and vitreoretinal interface (Fig. 1). The vitreous is a 
highly hydrated gel-like matrix of intertwined collagen fibres and gly-
cosaminoglycans [11,12]. Collagen fibrils maintain the gel state of the 
vitreous, whereas hyaluronic acid provides the swelling pressure by its 
charged carbohydrate chains that attract water and counter ions 
[13,14]. The vitreous humour restricts mobility of nanoparticles and the 
most pronounced effects are seen with cationic nanocarriers [15–19]. 
Overall, particle characteristics are important for their mobility in the 
vitreous [15]. 
Vitreoretinal interface limits material permeation from the vitreous 
into the retinal layers. This interface is composed of 1) cortical vitreous, 
2) inner limiting membrane (ILM) (the innermost boundary of the 
retina) and 3) expanded Müller cell footplates [20]. Cortical vitreous 
with high collagen concentration is a thin layer (100–300 μm) that runs 
parallel to the ILM [14]. Müller cells are glial cells which span 
throughout the retina from vitreal side to the distal side of the outer 
nuclear layer [5,8]. The major components of ILM are collagen type IV, 
laminin and fibronectin, but the composition and thickness varies 
among species and disease states [11,20–22]. ILM forms a physical 
barrier at the vitreoretinal interface [16,23]. Several studies have re-
ported viral and non-viral gene delivery to the retinal targets in rodents 
[23–25], but the ILM in mice, and rats is thin (<0.1 μm) resembling 
foetal human ILM [22]. Therefore, the results from rodent eyes are not 
representative for retinal drug delivery in larger species with different 
ILM structure. Thus, improved understanding of retinal permeation of 
nanoparticles is needed. 
In this study, we investigated systematically the retinal permeation 
of nanoparticles in bovine eyes. Liposomes were used, since they are 
well-documented nanoparticles for drug and gene delivery. We studied 
the retinal penetration of light-activated liposomes that are based on the 
use of indocyanine green (ICG) as triggering agent for light activated 
drug release [26]. Given the promising vitreal mobility of anionic and 
neutral liposomes [15], we evaluated how properties of such liposomes 
(particle size, surface charge, surface coating) affect their retinal 
permeation. Two types of ex vivo bovine explants were used: retinal 
model without vitreous and vitreoretinal explant with intact entire vit-
reoretinal interface as developed by Peynshaert et al. [27]. Herein, we 
report the features that determined the permeation of liposomes through 
vitreoretinal interface. This information helps the design of retinal drug 
delivery systems. 
2. Materials and methods 
2.1. Materials 
1,2-Distearoyl-sn-glycero-3-phosphoglycerol (DSPG), 1,2-dipalmi-
toyl-sn-glycero-3-phosphocholine (DPPC), 1,2-distearoyl-sn-glycero-3- 
phosphocholine (DSPC), 1-stearoyl-2-hydroxy-sn-glycero-3-phospho-
choline (Lyso PC), 1,2-distearoyl-sn-glycero-3 phosphoethanolamine 
(DSPE), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy 
(polyethylene glycol)-2000] (DSPE-PEG), 1,2-dioleoyl-3-trimethylam-
monium-propane (DOTAP) and 1,2-dioleoyl-sn-glycero-3-phosphoetha-
nolamine-N-Cyanine 5 (Cy5-PE) were purchased from Avanti Polar 
Lipids, Inc. (Alabaster, AL, USA). The extruder was from Avanti Polar 
Lipids (Alabaster, AL, USA) and the 30 nm, 50 nm and 100 nm, Nucle-
pore® polycarbonate membranes (diameter 19 mm) were bought from 
Whatman Int. Ltd. (Maidstone, England). 75 mm Transwell® with 0.4 
μm Pore Polycarbonate Membrane Insert (3419) was obtained from 
Corning™. Disposable base molds (41742) were acquired from Sham-
don™. Biopsy punch (10 mm) was purchased from Robbins Instruments, 
Catham, US. Anti-Collagen IV antibody (ab6586) was purchased from 
Abcam. Hoechst (33342) and AlexaFluor® 488 labelled secondary 
antibody (A11034) was provided from Invitrogen™, USA. Tissue culture 
materials were from Gibco™: Neurobasal®-A medium (10888022), 
carbon dioxide independent medium (18045088), B-27® supplement 
(17504044), Penicillin-streptomycin (15140122), L-Glutamine 
Fig. 1. Schematic representation of the eye with detailed retinal structure. Vitreous and vitreoretinal interface are the first barriers to retinal delivery of nano-
particles after intravitreal injection. Retinal layers: inner limiting membrane (ILM), nerve fibre layer (NFL), ganglion cell layer (GCL), inner plexiform layer (IPL), 
inner nuclear layer (INL), outer plexiform layer (OPL), outer nuclear layer (ONL), photoreceptors layer (PRL), retinal pigment epithelium (RPE). 
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(25030081). Chloroform and methanol used in the lipid stock solutions, 
HEPES (4- (2-hydroxyethyl) piperazine-1-ethanesulfonic acid) were 
purchased from Sigma-Aldrich. All reagents were analytical grade. 
2.2. Liposome preparation 
Lipids (10 μmol) at various molar ratios (Table 1) were dissolved in 
chloroform prior to liposome preparation. Liposomes were formulated 
by thin film hydration method followed by extrusion as previously re-
ported [15]. In brief, lipid mixture solutions were placed in rotary 
evaporator to remove the organic solvent at 65 ◦C under nitrogen flow 
condition by gradually reducing the pressure below 100 mbar. The thin 
lipid film was formed and hydrated by 500 μl of HEPES buffer saline 
solution (20 mM HEPES and 140 mM NaCl, pH 7.4) in water bath at the 
same temperature. Liposomes were then extruded 11 times at 65 ◦C 
through polycarbonate filter membranes with the pore size of 30 and 50 
or 100 nm using a syringe-type mini-extruder followed by immediate 
cooling down and stored at 4 ◦C. In anionic liposome preparation, DSPC 
was partially replaced by DSPG to have the final 10% molar ratio of 
negatively charged lipid in the lipid composition. Indocyanine green 
(ICG) at 1:50  molar ratio (to total lipids) was integrated in the lipid 
bilayer by dissolving ICG in methanol and adding it to the lipid mixture 
in chloroform prior to evaporation of the organic solvent. EE% of ICG 
was not measured due to the rapid degradation of non-capsulated ICG in 
aqueous solution; however, our previous molecular dynamics simula-
tions [26] indicate that ICG strongly prefers to be localized in the lipid 
bilayer indicating probable high EE%. Cy5-PE (0.5 mol%) was applied to 
label the liposomes. 
2.3. Particle size and ζ-potential analysis 
The particle size was measured by dynamic light scattering (DLS) 
using Malvern Zetasizer APS automated plate sampler (Malvern In-
struments Ltd., Malvern, United Kingdom). Data acquisition was per-
formed with Malvern DTS v7.01 software and the result were reported as 
size distribution by particle number and polydispersity index. Prior to 
measurement, each sample was diluted at 1:10 v/v ratio in HEPES buffer 
(pH 7.4) and analysed three times with 13 sub-runs. The zeta potential 
was determined using the same dilution ratio at room temperature with 
a Zetasizer ZS v7.1.1 (Malvern Instruments Ltd.). 
2.4. Preparation of bovine retinal explant without vitreous (R-explant) 
Fresh bovine eyes were provided by a local abattoir and transported 
in cold carbon dioxide (CO2) independent medium. Extra-ocular con-
nective tissues were removed and the eyes were shortly immersed in 
20% ethanol and kept in 4 ◦C CO2 independent medium until dissection. 
The sclera was punctured approximately 10 mm below the limbus using 
21 G needle and cut circumferentially with curved surgical scissors. The 
vitreous was gently removed and the posterior eyecup was filled with 
cold medium in order to avoid drying. The eyecup was then cut along the 
large veins in order to obtain 4 flaps while submerging the whole 
structure in medium. Next, a biopsy punch (10 mm) was used to cut 
circular pieces of retina from each flap followed by gentle pipetting of 
the medium underneath the cut surface, thus allowing isolation of the 
retina. Two retinal explants were transferred to 75 mm Transwell® 
insert and placed on the filter with photoreceptors facing down (Fig. S1). 
The explants were nourished by adding 10 ml of medium below the filter 
(Neurobasal®-A medium supplemented with 2% L-Glutamine, 1% B- 
27® supplement and 2% Penicillin-streptomycin). 
2.5. Preparation of vitreoretinal bovine retinal explant (VR-explant) 
The VR-explant with attached vitreous was prepared as described 
earlier [27]. This method maintains the intact ILM during the prepara-
tion. Briefly, after removal of extraocular tissues, the eyes were trans-
ferred to a beaker with CO2 independent medium at room temperature 
and, thereafter, incubated for 10 min in a 37 ◦C water bath. Such in-
cubation period is essential as it facilitates the smooth separation of 
retina from the RPE-choroid while maintaining attached vitreous on the 
retina. The eye was dissected as explained above, but unlike the R- 
explant, the vitreous gel was retained in the posterior eyecup. Next, the 
retina with vitreous was gently separated from the choroid at the edge of 
the eyecup toward the optic nerve. The whole structure was then slid 
into a petri dish filled with 4 ◦C CO2 independent medium (the vitreous 
facing upwards). VR-explants were cut into several pieces (around 1.5 
cm2) with a surgical blade while they were submerged in the medium. 
Each explant was then transferred to a 75 mm Transwell® filter followed 
by addition of the supplemented Neurobasal®-A medium under the 
filter (Fig. S1). Finally, excess of vitreous gel, adjacent to the explant, 
was aspirated with Pasteur pipette and removed by scissors so that the 
explant was ready for IVT injections of liposomes. 
2.6. Retinal explant treatment with liposomes 
The explants were treated with liposomes immediately after prepa-
ration. In R-explant, 10 μl of labelled liposome (3 mg/ml) was placed 
carefully on top of the retinal explant in order to assure that the 
formulation covers the explant sufficiently without overflow across the 
edges. Given the vitreous is attached to the retina in the VR-explant, the 
liposome solution (7 mg/ml) was injected intravitreally into this model. 
Four injections of 50 μl were performed horizontally to avoid retinal 
damage and prevent direct delivery of the particles into the retina. 
Transwells® were then placed in the incubator with 5% CO2 at 37 ◦C and 
incubated for 24 h or 48 h. 
2.7. Cryosectioning, immunohistochemistry and imaging 
After the incubation period, retinal explants were fixed by cutting 
out the Transwell® filter surrounding the explant, placing the filter with 
explant attached in a 6-well plate with 4% paraformaldehyde (PFA) and 
incubating the explants for 2 h at 4 ◦C. 
Table 1 
Lipid composition, associated molar ratios and physicochemical properties of ICG-liposomes. The formulations are categorized based on the particle size and surface 
charge (A: anionic and N: neutral).  
Formulation Lipid composition Molar ratios Size (nm) PdI ζ-Potential (mV) 
≤50 nm 
Anionic A1-PEG DPPC:DSPG: Lyso-PC:DSPC:DSPE-PEG:ICG 75:10:10:5:4:2 41.5 ± 7.7 0.182 − 28.2 
A2 DPPC:DSPG:Lyso-PC:DSPC:DSPE:ICG 75:10:10:5:4:2 48.1 ± 4.9 0.107 − 36.8 
Neutral N1-PEG DPPC:DSPC:Lyso-PC:DSPE-PEG:ICG 75:15:10:4:2 56.3 ± 5.5 0.211 − 3.1 
N2 DPPC:DSPC:Lyso-PC:DSPE:ICG 75:15:10:4:2 51.32 ± 14.2 0.138 − 7.7  
≥100 nm 
Anionic A3-PEG DPPC:DSPG:Lyso-PC:DSPC:DSPE-PEG:ICG 75:10:10:5:4:2 107.2 ± 6.5 0.053 − 27.6 
A4 DPPC:DSPG:Lyso-PC:DSPC:DSPE:ICG 75:10:10:5:4:2 100.7 ± 1.1 0.039 − 57.9 
Neutral N3-PEG DPPC:DSPC:Lyso-PC:DSPE-PEG:ICG 75:15:10:4:2 113.1 ± 14.3 0.068 − 3.4 
N4 DPPC:DSPC:Lyso-PC:DSPE:ICG 75:15:10:4:2 112.6 ± 8.8 0.042 − 6.7  
S. Tavakoli et al.                                                                                                                                                                                                                                
Journal of Controlled Release 328 (2020) 952–961
955
Thereafter, the fixative was discarded and the explants were cry-
opreserved following this scheme: 30% sucrose (overnight, 4 ◦C); a 1:1 
solution of Tissue-Tek® O.C.T/30% sucrose (3 h, 4 ◦C); pure O.C.T (3 h; 
room temperature). This special cryopreservation protocol was devel-
oped to prevent separation of the vitreous layer from the retinal tissue 
during cryosection cutting. After cryopreservation the explants were 
transferred to cryomolds, embedded in fresh O.C.T and snap frozen by 
submerging the cryomolds in isopentane cooled with dry ice. Subse-
quently, cryoblocks were removed from the mold and cut at a thickness 
of 16 μm with a cryostat (Leica CM3050s). Cryosections were obtained 
from 4 different explant sites. From each location, 6 sections were pre-
pared to obtain 24 cryosections per explant. 
To stain the retinal sections, 5% goat serum in PBS was prepared as a 
blocking solution. Next, each section was incubated in 50 μl of blocking 
solution for 1 h at room temperature followed by overnight incubation 
with rabbit anti-collagen IV antibody (50 μl, 1:200) at 4 ◦C. The sections 
were then labelled with Alexa Fluor™ 488-tagged goat anti-rabbit sec-
ondary antibody (50 μl, 1:500) and Hoechst at 10 μg/ml for 1 h at room 
temperature. Lastly, retinal sections were mounted in antifade mounting 
medium (Vectashield®, Vector Laboratories, CA, US) and stored at 4 ◦C 
until imaging. Visualization and imaging were performed with a 
confocal microscope (Leica TCS SP8) using 20× (HC PL APO 20×/0.75 
IMM CORR CS2) and 93× (HC PL APO 93×/1.30 mot CORR STED 
WHITE) objectives. 
Images were analysed by FIJI (imageJ 1.51, NIH) and the number of 
particles for the semi-quantitative analyses were counted according to a 
reported method [27]. Descriptive statistical analysis was performed 
using GraphPad Prism 8.2.1 in order to define quartiles of the data 
(median, 25th and 75th percentile). Accordingly, we categorized the 
retinal penetration into high, moderate and low levels, based on the 
number of liposomes per 1000 μm2 of retinal section: high (> 42), 
moderate (7–42) and low (< 7) per region of interest. 
3. Results 
3.1. Characterization of liposomes 
The physicochemical properties of liposomes including lipid 
composition, hydrodynamic diameter (size), the polydispersity index 
(PdI), and the ζ -potential are presented in Table 1. Surface charge (ζ 
-potential) was altered by changing the lipid composition. ICG- 
liposomes showed similar values of particle size and ζ -potential mea-
surements comparing to the controls [15]; hence, ICG did not have 
significant effect on physicochemical characteristic of the particles. 
Likewise, we did not observe any difference in particle size and surface 
charge between Cy5-labelled and unlabelled liposomes. Liposomal for-
mulations had homogenous distribution (PdI < 0.2). 
3.2. Effect of nanoparticle surface on their retinal distribution 
As anionic and neutral liposomes diffuse freely in the vitreous hu-
mour [15], we investigated their retinal penetration using bovine retinal 
explant models. The liposomes were categorized based on PEG coating, 
size, and surface charge (Table 1). 
Firstly, the liposomes were applied on conventional retinal explants 
(“R-explant”) without vitreous humour. Thereafter, the VR-explant with 
the vitreous attached to the retina was applied for the permeation study 
to rule out the possible influence of ILM damage during the removal of 
the vitreous. Our data shows that PEGylated (A1-PEG, N1-PEG) small 
liposomes (41.5 nm and 56.3 nm, respectively) successfully entered the 
retina in R-explant (Fig. S2). These liposomes were further investigated 
with the VR-explants. Since retinal permeation showed differences 
among explants and regions within one explant, at least 32 images were 
analysed to validate the results in Fig. 2. Both anionic (A1-PEG) and 
neutral (N1-PEG) liposomes permeated through retinal layers, but the 
distribution of the liposomes was not even in all layers and they were 
mostly located in the inner retina. We also observed the signs of cell 
localization of liposomes in ganglion cell layer (GCL) (Fig. 2B). Ac-
cording to the semi-quantitative analysis, retinal penetration of anionic 
liposomes (A1-PEG) was moderately higher than that of neutral lipo-
somes (N1-PEG). 
To examine the effect of surface coating on the retinal transfer, we 
compared the non-PEGylated and PEGylated anionic and neutral lipo-
somes within the same size range (< 50 nm). In R-explant, both lipo-
somes showed comparable retinal penetration, as they were able to 
reach and migrate throughout the inner retinal layers, but the distri-
bution seems to be restricted within GCL (Fig. S2, Fig. 3A: R-explant). In 
VR-explant, we saw variations between retinal sections that were 
incubated with liposomes devoid of PEG suggesting less efficient retinal 
permeation as compared with PEGylated liposomes (Figs. 2–3). Even 
though some retinal sections showed permeation of A2 and N2, the 
retinal distribution was less consistent than with PEGylated liposomes 
(Fig. 3A–B). In conclusion, PEG-coating facilitates retinal permeation of 
the liposomes. 
3.3. Effect of liposome size on retinal distribution 
Next, we studied the permeation of differently sized liposomes into 
the bovine explants. First, R-explants were used. Here, we investigated 
the retinal transfer of anionic PEGylated (A3-PEG), anionic non- 
PEGylated (A4), neutral PEGylated (N3-PEG) and neutral non- 
PEGylated (N4) liposomes with a size range ≥ 100 nm (Table 1). 
Regardless of surface coating and charge these liposomes failed in 
crossing the ILM barrier and retinal entry (Fig. 4). Interestingly, the 
retinal penetration of larger liposomes was only detected in the cry-
osections with compromised ILM implying the barrier role of ILM 
(Fig. S3). 
3.4. Influence of incubation time on retinal distribution of liposomes 
Although 24 h of incubation seemed sufficient for the liposomes to be 
taken up by the ex vivo R and VR-explants, we examined the influence of 
prolonged exposure. Retinal distribution of small anionic PEG-coated 
liposomes (A1-PEG) was studied after 48 h of incubation on VR 
bovine explant. Cryosection images showed higher extent of retinal 
penetration. This was seen as reduced brightness in the vitreous and 
ILM, suggesting lower level of liposome entrapment in the ILM. 
Compared to the limited number of PEGylated liposomes in outer retinal 
layer after 24 h (Fig. 2A), more liposomes migrated to the deeper retinal 
layers and the outer retina during 48 h (Fig. 5). Moreover, a detailed 
confocal image at higher magnification (Fig. 5 bottom row) shows again 
co-localization of liposomes with ganglion cells. 
In the experiment, ≈100 nm anionic and PEGylated liposomes (A3- 
PEG) were studied with ex vivo retinal R-explant for 48 h to investigate 
their possible retinal permeation during longer time. However, the re-
sults did not show any retinal transfer even after 48 h (Fig. 6) indicating 
that vitreoretinal interface blocks the retinal transfer of liposomes with 
the particle size of over 100 nm. 
4. Discussion 
Visual impairment and blindness are caused by various retinal dis-
eases, but the delivery of therapeutics to the retina is limited by the 
anatomical and physiological barriers. The most common retinal ther-
apies involve IVT injections of steroids [28] and anti-VEGF antibodies 
[29,30]. These treatments involve frequent IVT injections on chronic 
basis. For corticosteroids, IVT implants have been used for prolonged 
IVT dosing intervals, but with exception of few explants such as Ozur-
dex®, they have not gained wide clinical use. Consequently, alternative 
approaches are needed to prolong the dosing intervals and to enable 
retinal targeting of IVT therapeutics. IVT injected nanoparticles may 
prolong ocular drug retention and provide sustained drug delivery to the 
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retinal targets. Recently, we developed ICG-containing light-activated 
liposomes that allow spatial and temporal control of contents release 
[26]. This approach is interesting for the controlled drug delivery into 
the retina. Nonetheless, for the effective retinal therapy, liposomes must 
permeate successfully from the vitreous to the retina. Previously, we 
showed the impact of physical-chemical features on vitreal mobility of 
lipid-based nanostructures (e.g. liposomes) [15]. As anionic and neutral 
liposomes, with and without ICG, permeate easily in the vitreous, we 
investigated their ability to cross the vitreoretinal interface. We did not 
include cationic liposomes in this study, because the positive charge 
limits the vitreal mobility of particles [15–17,19]. Furthermore, their 
permeation across the vitreoretinal interface is blocked by their in-
teractions with negatively charged ILM components, such as heparan 
sulphate [23,31,32]. 
Previous studies have reported successful retinal delivery of viral and 
non-viral nanocarriers, but these experiments were conducted mostly in 
rodents (rats, mice) that have thinner ILM than larger animals and 
humans [22,33]. Therefore, we applied bovine retinal explants to obtain 
more relevant and systematic data on retinal permeation of liposomes. 
The bovine vitreous is comparable to its human counterpart [19,34–36] 
and the thickness of bovine ILM is similar with the adult human and non- 
human primate ILM (the thickness can reach up to 4 μm in posterior pole 
based on atomic force microscopic images) [21,27,33,37,38]. These are 
very different values from the ILM thickness in adult mouse (< 0.1 μm) 
and human foetus (≈ 0.07 μm) [21,31,33,39]. 
The barrier role of ILM was demonstrated in this study, also in the 
experiments with broken explant ILM (Fig. S3). In those cases, even 100 
nm liposomes distributed to the retina. The structure of the ILM may also 
be influenced by age and retinal degeneration [40]. In some diseases, 
such as diabetic retinopathy, increased permeability of ILM has been 
observed. Even though disease-induced leakiness of ILM might increase 
retinal permeation of nanoparticles, this situation may be relevant only 
in the case of late-stage severe disease. As there are numerous retinal 
diseases and levels of their seriousness, the issue of disease state vs 
permeation is fragmented and complicated. To make robust retinal de-
livery system, applicable to many diseases and their different stages, one 
should not rely on hypothetical enhanced permeability across ILM, but 
rather develop a delivery system that would permeate even through the 
intact ILM. Overall, we are convinced that our data herein is transla-
tionally more relevant than the previous published rodent data. 
Our work showed that anionic and neutral liposomes of ≈50 nm 
penetrate into the retina and distribute in the inner retina, and to some 
Fig. 2. Retinal distribution of PEGylated negatively charged (A1-PEG) and neutral (N1-PEG) ≈ 50 nm liposomes in bovine vitreoretinal explant 24 h post-IVT 
injection. (A) Representative confocal microscopy images of cryosections displaying the permeation of Cy5-labelled A1-PEG and N1-PEG in retinal layers (red). 
The ILM is labelled with anti-collagen type IV antibody (green) which also stains the retinal blood vessels, highlighted with “ * ”. The vitreous can be seen as 
transparent layer in transmission imaging which is well aligned along the ILM while it appears in bright red colour due to the high load of Cy5-labelled particles in 
merged channel mode. Nuclei are stained with Hoechst (blue). (B) Representative image of retinal cross-section at higher magnification showing the co-localization 
of liposomes with ganglion cells (highlighted with white arrowheads). Scale bar: 50 μm. (C) Semi-quantitative analysis of retinal distribution of neutral and anionic 
PEGylated liposomes in vitreoretinal explant after 24 h of incubation. The numbers refer to the liposomes within the region of interest (1000 μm2) (n = 3). (For 
interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) 
Fig. 3. (A) Representative cryosection images showing the retinal distribution of non-PEGylated liposomes in ex vivo bovine explants. The confocal microscopy 
images of VR-explants demonstrate retinal sections without retinal permeation of liposomes. ILM and retinal blood vessels are stained with anti-collagen type IV 
antibody (green), the nuclei are stained with Hoechst (blue) and particles labelled with Cy5 are shown in red. Scale bar: 50 μm. (B) Semi-quantitative analysis of 
retinal transfer across the ILM comparing the distribution of anionic PEGylated and non-PEGylated liposomes in vitreoretinal explants after 24 h of incubation. P 
value <0.001 by an unpaired t-test. (n = 3). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of 
this article.) 
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extent also in the outer retinal layers (Fig. 2A). However, larger lipo-
somes (≈100 nm) were not able to cross vitreoretinal interface, sug-
gesting that the mesh size of the ILM may be between 50 nm and 100 
nm, which is in line with previously shown hampered permeation of 
polystyrene bead (100 and 200 nm) into the bovine retina [27]. It is 
worth mentioning that the particle size distribution of the liposomes is 
narrow (PdI < 0.2) and our recent proteomics data shows that the 
protein corona results in only 10–12% increase in the liposome size in 
the vitreous [15]. The mesh size in the bovine ILM seems to be much 
smaller than the mesh size in the vitreous (≈500 nm) [19] or the sizes of 
Fig. 4. Representative cryosection images display the failure in retinal distribution of PEGylated (upper row) and non-PEGylated anionic formulations (bottom row) 
of ≥100 nm liposomes in ex vivo bovine R-explants. ILM and retinal blood vessels were visualized by staining with anti-collagen type IV antibody (green), the nuclei 
were labelled with Hoechst (blue), and Cy5-liposomes are shown in red. Scale bar: 50 μm. (n = 3). (For interpretation of the references to colour in this figure legend, 
the reader is referred to the web version of this article.) 
Fig. 5. Representative distribution of PEGylated anionic liposomes (A1-PEG) throughout the retinal layers 48 h post-IVT injection in ex vivo bovine VR-explant. 
Cryosection images show the localization of liposomes in inner and outer retina. At 93× magnified confocal image, localization of liposomes in a ganglion cell is 
evident (highlighted with white triangle). ILM was stained with anti-collagen type IV antibody (green) which also labels the retinal blood vessels, nuclei were stained 
with Hoechst (blue) and Cy5-liposomes are displayed in red. Scale bar: 50 μm. (n = 3). (For interpretation of the references to colour in this figure legend, the reader 
is referred to the web version of this article.) 
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particles that permeate across the vitreoretinal surface of rodents 
(100–420 nm) [9,23,41–44]. Our observations are attributed to denser 
structure of ILM and high concentration of hyaluronic acid in cortical 
vitreous [20,39]. The mesh size in bovine and human ILM have been 
reported to be similar although the bovine vitreous is more viscous 
compared to human vitreous [45], further supporting the translational 
value of this study. 
Our results clearly demonstrate more consistent retinal permeation 
of PEG-coated liposomes, as compared to the liposomes without PEG. 
Particularly in the case of non-PEGylated liposomes, substantial varia-
tion was seen in liposome permeation to the VR-explant. Apparently, 
hydrophilic PEG coating somehow reduces liposome binding with ILM, 
thereby facilitating retinal distribution. Previously, it was reported that 
the PEG coating with a molecular weight of ≥2 kDa facilitates the 
transport of nanoparticles across the mucosal barrier [46]. Given the 
similar structural component of vitreous/ILM to mucous (negatively 
charged polysaccharide network in water), higher retinal penetration of 
PEG-coated particles may be attributed to the same mechanism. None-
theless, there are only limited data about the PEG effects on the retinal 
permeation. Previously, positive impact of hyaluronic acid coating on 
nanoparticle’s distribution into the retina was shown, which support 
this hypothesis according the superior penetration of hyaluronic acid- 
coated nanoparticles compared to the non-coated counterparts. Large 
hyaluronic acid-coated liposomes, however, failed to permeate into the 
retina [47]. Therefore, both coating and particle size are important 
determinants of retinal particle permeation across the ILM. 
Cellular interactions of nanoparticles, such as liposomes, within the 
retina are an interesting but sparsely studied phenomenon. In principle, 
Müller cells could serve as an avenue for nanoparticle transfer from the 
inner retina to the outer retina, if the particles are transported within 
these cells and exocytosed in the outer retina. Anionic particles have 
higher interaction with Müller cells than the neutral particles [23], 
possibly contributing to the moderately improved retinal penetration of 
anionic liposomes (Fig. 2C). Previously, higher phagocytic uptake of 
charged particles as compare to the neutral ones was shown in the 
Müller cells [23,49]. Such a mechanism was suggested previously for 
retinal distribution of intravitreal nanoparticles [7,50]. Intercellular 
communication of retinal cells with extracellular vesicles might also 
contribute to the distribution of liposomes [3,44]. Interestingly, we 
observed co-localization of light-activated liposomes (< 50 nm) with 
ganglion cells (Figs. 2 and 5). Targeted delivery to ganglion cells may 
have important implications in the treatment of glaucomatous retinal 
degeneration, since these cells play a key role in the retinal pathology of 
glaucoma [48]. 
We demonstrate here the impact of liposomal surface coating, charge 
and size on their retinal permeation. In addition, other factors may affect 
liposomal retinal distribution, but they are poorly known. Distribution 
of small liposomes into the deep retina (see outer nuclear layer in Fig. 5) 
could be attributed to the short hydrocarbon chain length (e.g. DPPC) in 
the light-activated liposomes. Short hydrocarbon chains and lyso-PC 
yield more fluid bilayers [26,51] that may facilitate cellular uptake 
and biological transport in the retina. Moreover, the particle shape may 
influence retinal permeation through sieve-like ILM. Accordingly, 
retinal permeation of tubular polymeric nanoparticles was shown 
recently in bovine retina [52]. 
Overall, retinal particle penetration is a multifactorial process in 
which ILM plays an important role. The factors include nanoparticle 
characteristics and endogenous factors, such as cellular activity, age- 
and disease related changes, and regional morphological differences. In 
this regard, our data provide systematic data on the effects of liposomal 
characteristics on ILM permeation, also demonstrating that the bovine 
explant model is much tighter than previously published rodent models. 
Thus, we believe that this study is a step forward in understanding the 
barrier properties at vitreoretinal interface. 
5. Conclusions 
We characterized liposomal permeation from the vitreal side to the 
retina in bovine explant models. Compared to the vitreal barrier, the 
vitreoretinal interface and the ILM represent significant barriers for 
particle penetration. Our data indicate that small liposomes (≈50 nm) 
permeate to the retina, whereas larger liposomes (≈100 nm) do not. 
Furthermore, PEGylation and anionic surface charge are beneficial for 
retinal liposome distribution. Our results indicate that the vitreoretinal 
interface is stronger barrier than previously thought based on the rodent 
studies. However, more in-depth investigations are needed to elucidate 
the roles of different cells in liposome localization in the retina. In 
conclusion, our observations highlight the importance of employing 
representative animal models in retinal distribution studies and provides 
systematic understanding on the roles of particle characteristics in 
retinal liposome permeation. 
Acknowledgement 
Shirin Tavakoli, Arto Urtti and Stefaan de Smedt acknowledge the 
research support from European Union’s Horizon 2020 research and 
innovation program Marie Sklodowska-Curie Innovative Training Net-
works (ITN) NANOMED (grant no. 676137). Grant support from Russian 
Government Mega-Grant14.W03.031.0025 “Biohybrid technologies for 
modern biomedicine” to Arto Urtti is acknowledged. Tatu Lajunen ac-
knowledges additional support from Business Finland (#4208/31/ 
2015), Orion Research Foundation (#9-8214-9), Phospholipid Research 
Center, Instrumentarium Science Foundation and Silmäsäätiöiden Toh-
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